NIH Reporter #5R01CA263806-05

NCI Research Grant for Therapies Targeting Cisplatin-Induced Neurotoxicity

This opportunity is a research grant offered by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), focused on reducing neurotoxicity from cisplatin-based cancer treatments. - Government Buyer: - National Cancer Institute (NCI), NIH - Purpose: - Research grant to develop therapeutics targeting p38 and JNK MAPK pathways to mitigate neurotoxic side effects of cisplatin in ovarian and other cancer treatments - Products/Services Requested: - Academic research services, including: - In vitro and in vivo studies - Behavioral analysis - Translational research - Notable Requirements: - Open to academic institutions and researchers - No specific license or commercial product requirements - Research to be conducted at University of California-Irvine - OEMs and Vendors: - No OEMs or commercial vendors specified, as this is a grant for academic research - Estimated contract value: $601,825

Description

This is a research grant opportunity focused on mitigating neurotoxicity caused by cisplatin in ovarian cancer treatment. The project involves in vitro and in vivo studies, behavioral analysis, and translational research to develop therapeutics targeting the p38 and JNK pathways. The funding is provided by the NIH/NCI with a total award amount of $601,825. The research aims to reduce neurotoxic side effects in women with ovarian and other cancers.

View original listing